Key Takeaways
Law firm Kirby McInerney LLP has launched an investigation into Erasca, Inc. (NASDAQ:ERAS) after allegations of patent infringement and trade secret misappropriation caused the company's stock to fall 48 percent.
"The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices," Kirby McInerney said in a press release.
The investigation was prompted by an April 28, 2026 disclosure from Erasca. The company announced it had received a letter from Revolution Medicines, which alleged that Erasca's cancer drug candidate, ERAS-0015, infringes on a Revolution patent and involves trade secret misappropriation. Following the news, Erasca's shares dropped $9.25, falling from $19.15 to close at $9.90.
The 48% single-day collapse in share price represents a significant loss of market capitalization and exposes Erasca to potential litigation. While no lawsuit has been filed, the firm is soliciting information from investors who purchased Erasca securities.
The investigation creates significant legal and financial uncertainty for Erasca, potentially leading to a class-action lawsuit and further stock volatility. Investors will be watching for any official legal filings or a response from Erasca's management regarding the allegations.
This article is for informational purposes only and does not constitute investment advice.
